Baird raised the firm’s price target on Regeneron (REGN) to $637 from $587 and keeps a Neutral rating on the shares. The firm updated its model following its Q3 beat which came with visibility into Eylea HD sBLA timelines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $818 from $781 at Bernstein
- Regeneron price target raised to $865 from $815 at Guggenheim
- Regeneron price target raised to $627 from $543 at BofA
- Cautious Outlook on Regeneron Amid Eylea Erosion and Medicare Policy Risks
- Regeneron Pharmaceuticals Faces Financial Risks Amid Tariff and Trade Challenges